On December 20, 2021 Cellesce reported the promotion of Vicky Marsh-Durban as the company’s first full time CEO (Press release, Cellesce, DEC 20, 2021, View Source [SID1234597459]). Vicky joined Cellesce in 2019 as Lead Scientist and was promoted to COO and the Board in Jan ’21.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Victoria Marsh Durban

Vicky completed her Ph.D. at Cardiff University in 2008 in the field of cancer genetics. Subsequently she moved to University of California, San Francisco (UCSF), where she held a post-doctoral research scholarship investigating targeted therapeutic approaches in malignant melanomas. In 2014 she was enticed back to Cardiff to take up a Research Fellowship at the European Cancer Stem Cell Research Institute. In 2016 Vicky joined ReNeuron in her first commercial role, as Principal Investigator and Head of Cell Biology.

Vicky has played a vital role in helping the Company to make significant commercial and scientific progress despite the challenges of the CV-19 global pandemic and we are all excited that she will now take full responsibility for running the company as it enters the next phase of its development.

At the same time Paul Jenkins will be stepping down from the Board. Paul has made an invaluable contribution to Cellesce and the Board would like to place on record its thanks for all his hard work over the last 2 years. We are delighted that he will continue to support the Company in a consultancy capacity going forward.